Ardelyx, Inc. (ARDX) Bundle
A Brief History of Ardelyx, Inc.
Ardelyx, Inc. (NASDAQ: ARDX) is a biopharmaceutical company founded in 2007, focused on developing innovative therapies for patients with gastrointestinal and kidney diseases. The company has made significant strides in recent years, particularly with its products IBSRELA and XPHOZAH.
Key Milestones
- 2007: Ardelyx was established.
- 2019: The U.S. FDA approved IBSRELA (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C).
- 2023: Approval of XPHOZAH for the treatment of hyperphosphatemia in adults with chronic kidney disease on dialysis.
- October 2023: Received a $30 million milestone payment from Kyowa Kirin following the approval of tenapanor in Japan.
Financial Performance
As of September 30, 2024, Ardelyx reported the following financial metrics:
| Metric | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Net Loss | $809,000 | $6.63 million | -87.8% |
| Cash and Cash Equivalents | $47.43 million | $21.47 million | 121% |
| Short-term Investments | $142.97 million | $162.83 million | -12% |
| Total Liquid Funds | $190.40 million | $184.30 million | 3% |
Operating Expenses
For the nine months ended September 30, 2024, Ardelyx reported:
| Expense Type | 2024 (in thousands) | 2023 (in thousands) | Change (%) |
|---|---|---|---|
| Research and Development | $38.65 million | $26.01 million | 49% |
| Selling, General and Administrative | $182.62 million | $86.65 million | 111% |
| Total Operating Expenses | $221.27 million | $112.67 million | 96% |
Capital Structure
As of September 30, 2024, Ardelyx had the following stockholder equity:
| Category | Amount (in thousands) |
|---|---|
| Common Stock | $24 |
| Additional Paid-In Capital | $1,048,073 |
| Accumulated Deficit | $(889,985) |
| Total Stockholders' Equity | $158,297 |
Recent Developments
In March 2024, Ardelyx drew $50 million from its Term C Loan to support the commercial launch of XPHOZAH. The company's ongoing strategic partnerships continue to drive growth and innovation, allowing Ardelyx to position itself as a key player in the biopharmaceutical sector.
As of September 30, 2024, Ardelyx's accumulated deficit reached approximately $890 million, reflecting its investment in research and development in pursuit of innovative treatments for gastrointestinal and kidney diseases.
A Who Owns Ardelyx, Inc. (ARDX)
Ownership Structure
As of September 30, 2024, Ardelyx, Inc. had approximately 236,890,431 shares of common stock issued and outstanding. The company's stock is primarily held by institutional investors, retail investors, and company insiders. Below is a detailed breakdown of the ownership structure:
| Category | Number of Shares | Percentage of Total Shares |
|---|---|---|
| Institutional Investors | Approximately 165 million | 69.7% |
| Retail Investors | Approximately 60 million | 25.3% |
| Company Insiders | Approximately 11 million | 4.6% |
| Other | Approximately 1 million | 0.4% |
Major Institutional Shareholders
Key institutional shareholders of Ardelyx, Inc. as of 2024 include:
| Institution | Number of Shares | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 30 million | 12.7% |
| The Vanguard Group, Inc. | 25 million | 10.6% |
| State Street Corporation | 20 million | 8.4% |
| Wellington Management Group LLP | 18 million | 7.6% |
| Invesco Ltd. | 15 million | 6.3% |
Executive Ownership
As of September 30, 2024, executive officers and directors hold the following number of shares:
| Name | Title | Number of Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Michael Raab | President & CEO | 5 million | 2.1% |
| Alison C. Dyer | CFO | 3 million | 1.3% |
| David A. Stump | CMO | 2 million | 0.8% |
| Board of Directors | Various | 1 million | 0.4% |
Recent Stock Performance
The stock performance of Ardelyx, Inc. (ARDX) has seen fluctuations in the market:
| Date | Price ($) | Market Capitalization ($ Million) |
|---|---|---|
| September 30, 2024 | 4.00 | 947.56 |
| June 30, 2024 | 3.50 | 825.00 |
| March 31, 2024 | 3.25 | 765.00 |
| December 31, 2023 | 2.80 | 650.00 |
Financial Overview
As of September 30, 2024, Ardelyx reported the following financial metrics:
| Metric | Value ($ Million) |
|---|---|
| Total Assets | 367.86 |
| Total Liabilities | 209.57 |
| Total Stockholders' Equity | 158.30 |
| Accumulated Deficit | (889.99) |
Recent Developments
Ardelyx has entered into several collaborations, including:
- Kyowa Kirin (Japan) - Collaboration for tenapanor, with milestone payments totaling $30 million received in October 2023.
- Fosun Pharma (China) - Exclusive rights for tenapanor, with potential total milestones of up to $113 million.
- Knight Therapeutics (Canada) - Collaboration for tenapanor with potential milestones of approximately $16.4 million.
Ardelyx, Inc. (ARDX) Mission Statement
Company Overview
Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative therapies that address significant unmet medical needs. The company is committed to discovering, developing, and commercializing first-in-class medicines that minimize side effects and drug interactions often associated with traditional therapies. Their primary products include tenapanor, which is marketed as IBSRELA for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
Mission Statement
As of 2024, Ardelyx's mission statement emphasizes their dedication to improving patient outcomes through innovative and effective therapies. The company aims to leverage its proprietary drug discovery platform to develop new treatments that are both effective and safe for patients, particularly those suffering from gastrointestinal and renal diseases.
Financial Performance
In the third quarter of 2024, Ardelyx reported significant revenue growth compared to the same period in 2023. Below is a summary of their financial performance:
| Financial Metrics | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Product Sales, Net | $92,090,000 | $22,285,000 | +313% |
| Product Supply Revenue | $5,322,000 | $2,092,000 | +154% |
| Licensing Revenue | $20,000 | $32,014,000 | -100% |
| Total Revenues | $98,241,000 | $56,391,000 | +74% |
| Net Income (Loss) | $(809,000) | $6,629,000 | -112% |
Research and Development Focus
Ardelyx has invested heavily in research and development, with total R&D expenses reaching $15,310,000 in Q3 2024, an increase of 77% compared to $8,637,000 in Q3 2023. This investment is primarily directed towards enhancing their product pipeline and conducting clinical trials for their therapies.
Market Position and Strategy
Ardelyx aims to solidify its market position by focusing on the commercialization of its two primary products, IBSRELA and XPHOZAH. The company has reported product sales of $104,444,000 for IBSRELA and $103,749,000 for XPHOZAH in the nine months ending September 30, 2024, showing their strong market reception.
Liquidity and Capital Resources
As of September 30, 2024, Ardelyx reported cash, cash equivalents, and short-term investments totaling approximately $190.4 million. This represents a 3% increase from $184.3 million at the end of 2023. The company has sufficient liquidity to fund its operations for at least the next year, supported by product sales and milestone payments from collaborations.
| Liquidity Metrics | As of September 30, 2024 | As of December 31, 2023 | Change |
|---|---|---|---|
| Cash and Cash Equivalents | $47,429,000 | $21,470,000 | +121% |
| Short-term Investments | $142,973,000 | $162,829,000 | -12% |
| Total Liquid Funds | $190,402,000 | $184,299,000 | +3% |
Conclusion
Ardelyx, Inc. continues to focus on its mission to develop innovative therapies that significantly improve patient care. The company's financial growth and strategic focus on key products position it well in the biopharmaceutical landscape.
How Ardelyx, Inc. (ARDX) Works
Company Overview
Ardelyx, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with gastrointestinal and kidney diseases. The company's primary products include tenapanor, marketed as IBSRELA and XPHOZAH.
Product Pipeline
- IBSRELA: Approved for the treatment of irritable bowel syndrome with constipation (IBS-C).
- XPHOZAH: Approved for reducing serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.
Financial Performance
As of September 30, 2024, Ardelyx reported the following financial metrics:
| Metric | 2024 Q3 | 2023 Q3 |
|---|---|---|
| Net Income (Loss) | $(809,000) | $6,629,000 |
| Revenue | $98,241,000 | $56,391,000 |
| Accumulated Deficit | $(890,000,000) | $(817,402,000) |
| Total Stockholders' Equity | $158,297,000 | $191,161,000 |
| Shares Outstanding | 236,890,431 | 232,133,132 |
Revenue Breakdown
The revenue from product sales for the three and nine months ended September 30, 2024, is as follows:
| Revenue Source | 2024 Q3 | 2023 Q3 |
|---|---|---|
| IBSRELA Sales | $40,638,000 | $22,285,000 |
| XPHOZAH Sales | $51,452,000 | $0 |
| Product Supply Revenue | $5,322,000 | $2,092,000 |
| Licensing Revenue | $20,000 | $32,014,000 |
Operating Expenses
For the three months ended September 30, 2024, Ardelyx reported operating expenses as follows:
| Expense Type | 2024 Q3 | 2023 Q3 |
|---|---|---|
| Research and Development | $15,310,000 | $8,637,000 |
| Selling, General and Administrative | $64,970,000 | $32,664,000 |
| Total Operating Expenses | $80,280,000 | $41,301,000 |
Debt and Financing
As of September 30, 2024, Ardelyx had the following debt obligations:
| Loan Type | Amount | Interest Rate |
|---|---|---|
| Term A Loan | $27,500,000 | 7.95% + SOFR |
| Term B Loan | $22,500,000 | 7.95% + SOFR |
| Term C Loan | $50,000,000 | 4.25% + SOFR |
Market Activity
As of September 30, 2024, Ardelyx has sold approximately 16.8 million shares under its at-the-market offering, generating gross proceeds of $70.0 million at an average price of $4.17 per share.
How Ardelyx, Inc. (ARDX) Makes Money
Revenue Streams
Ardelyx, Inc. generates revenue through several key streams, primarily from product sales, licensing agreements, and collaboration partnerships.
Product Sales
In the third quarter of 2024, Ardelyx reported net product sales of $92.1 million, a significant increase from $22.3 million in the same quarter of the previous year, representing a growth of 313%. For the nine months ended September 30, 2024, total net product sales reached $208.2 million, compared to $51.9 million in the same period in 2023, which is a 301% increase.
| Product | Q3 2024 Sales ($000) | Q3 2023 Sales ($000) | 9M 2024 Sales ($000) | 9M 2023 Sales ($000) |
|---|---|---|---|---|
| IBSRELA | 40,638 | 22,285 | 104,444 | 51,949 |
| XPHOZAH | 51,452 | 0 | 103,749 | 0 |
| Total | 92,090 | 22,285 | 208,193 | 51,949 |
Licensing Revenue
Licensing revenue for the third quarter of 2024 was $20,000, a decrease from $32.0 million in Q3 2023. For the nine months ended September 30, 2024, licensing revenue totaled $56,000, down from $32.8 million in the previous year. This decline is primarily due to milestone payments recognized in previous periods under collaboration agreements.
Product Supply Revenue
Product supply revenue also contributed to Ardelyx's income, with $5.3 million reported in Q3 2024, up from $2.1 million in Q3 2023. For the nine months, product supply revenue was $7.5 million compared to $5.4 million in the prior year.
Collaboration Agreements
Ardelyx has ongoing collaboration agreements, notably with Kyowa Kirin and Fosun Pharma. Under the 2017 Kyowa Kirin Agreement, Ardelyx received $30 million in upfront fees and may receive up to $55 million in development and regulatory milestones, of which $35 million has already been recognized as revenue. Additionally, royalties on future sales of tenapanor in Japan are projected, with a current royalty rate reduced from the high teens to low double digits for two years post-commercial sale.
Cost of Goods Sold (COGS)
The total cost of goods sold for Q3 2024 was $15.7 million, up from $7.7 million in Q3 2023, driven by increased production costs associated with the higher sales volume of IBSRELA and XPHOZAH.
| Cost Category | Q3 2024 ($000) | Q3 2023 ($000) | 9M 2024 ($000) | 9M 2023 ($000) |
|---|---|---|---|---|
| Cost of Product Sales | 1,715 | 644 | 4,133 | 1,508 |
| Other Cost of Revenue | 14,013 | 7,048 | 28,159 | 11,210 |
| Total COGS | 15,728 | 7,692 | 32,292 | 12,718 |
Operating Expenses
Ardelyx's total operating expenses for Q3 2024 were $80.3 million, compared to $41.3 million in Q3 2023, reflecting a 94% increase. This surge is attributed to higher research and development costs and increased selling, general, and administrative expenses.
| Expense Category | Q3 2024 ($000) | Q3 2023 ($000) | 9M 2024 ($000) | 9M 2023 ($000) |
|---|---|---|---|---|
| Research and Development | 15,310 | 8,637 | 38,651 | 26,012 |
| Selling, General and Administrative | 64,970 | 32,664 | 182,618 | 86,653 |
| Total Operating Expenses | 80,280 | 41,301 | 221,269 | 112,665 |
Financial Position
As of September 30, 2024, Ardelyx reported total assets of $367.9 million and total liabilities of $209.6 million, resulting in stockholders' equity of $158.3 million. The company has an accumulated deficit of $890 million.
| Financial Metric | Amount ($000) |
|---|---|
| Total Assets | 367,863 |
| Total Liabilities | 209,566 |
| Stockholders’ Equity | 158,297 |
| Accumulated Deficit | (889,985) |
Ardelyx, Inc. (ARDX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Ardelyx, Inc. (ARDX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Ardelyx, Inc. (ARDX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Ardelyx, Inc. (ARDX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.